Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Puhr

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
European Urology Focus|July 21, 2017
Inflammation, Microbiota, and Prostate CancerMartin Puhr, Angelo De Marzo, William Isaacs, et al.
Oncotarget|August 4, 2016
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamideJulia Hoefer, Mohammady Akbor, Florian Handle, et al.
Cancer Research|September 10, 2009
Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathwaysMartin Puhr, Frédéric R Santer, Hannes Neuwirt, et al.
The American Journal of Pathology|March 28, 2012
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21Julia Hoefer, Georg Schäfer, Helmut Klocker, et al.
The American Journal of Pathology|June 10, 2023
The Oncogenic Protein Kinase/ATPase RIOK1 Is Up-Regulated via the c-myc/E2F Transcription Factor Axis in Prostate CancerFlorian Handle, Martin Puhr, Martina Gruber, et al.
International Journal of Medical Sciences|January 22, 2019
Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculatureAndreas Pircher, Georg Schäfer, Andrea Eigentler, et al.
Oncotarget|December 5, 2014
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cellsMartin Puhr, Julia Hoefer, Hannes Neuwirt, et al.
The American Journal of Pathology|March 11, 2021
MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP InhibitorsTobias Furlan, Alexander Kirchmair, Natalie Sampson, et al.
Molecular Oncology|January 31, 2017
The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancerKaren Hanrahan, Amanda O'Neill, Maria Prencipe, et al.
Cancer Biology & Therapy|August 2, 2018
Antidiabetic drugs influence molecular mechanisms in prostate cancerAndreas Pircher, Martin Zieher, Andrea Eigentler, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
European Urology Focus|July 21, 2017
Inflammation, Microbiota, and Prostate CancerMartin Puhr, Angelo De Marzo, William Isaacs, et al.
Oncotarget|August 4, 2016
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamideJulia Hoefer, Mohammady Akbor, Florian Handle, et al.
Cancer Research|September 10, 2009
Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathwaysMartin Puhr, Frédéric R Santer, Hannes Neuwirt, et al.
The American Journal of Pathology|March 28, 2012
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21Julia Hoefer, Georg Schäfer, Helmut Klocker, et al.
The American Journal of Pathology|June 10, 2023
The Oncogenic Protein Kinase/ATPase RIOK1 Is Up-Regulated via the c-myc/E2F Transcription Factor Axis in Prostate CancerFlorian Handle, Martin Puhr, Martina Gruber, et al.
International Journal of Medical Sciences|January 22, 2019
Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculatureAndreas Pircher, Georg Schäfer, Andrea Eigentler, et al.
Oncotarget|December 5, 2014
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cellsMartin Puhr, Julia Hoefer, Hannes Neuwirt, et al.
The American Journal of Pathology|March 11, 2021
MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP InhibitorsTobias Furlan, Alexander Kirchmair, Natalie Sampson, et al.
Molecular Oncology|January 31, 2017
The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancerKaren Hanrahan, Amanda O'Neill, Maria Prencipe, et al.
Cancer Biology & Therapy|August 2, 2018
Antidiabetic drugs influence molecular mechanisms in prostate cancerAndreas Pircher, Martin Zieher, Andrea Eigentler, et al.
Pageof 7